Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
SLT Beats Medications in Glaucoma – AAO 2024
A recent retrospective analysis of the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial data demonstrated that selective laser trabeculoplasty (SLT) as a first-line treatment significantly outperforms glaucoma medications in reducing the rate of visual field (VF) loss. This study,…
Study: Aromatherapy Eases Post-Surgery Anxiety and Pain
A recent study suggests that aromatherapy may effectively reduce postoperative anxiety and pain in patients undergoing oculoplastic procedures under monitored anesthetic sedation. Published in Ophthalmic Plastic and Reconstructive Surgery, this randomized controlled trial highlights the potential of aromatherapy as an…
De-escalated Chemo Effective for High-Risk Retinoblastoma
A recent study reveals that a shortened adjuvant chemotherapy regimen offers similar efficacy and improved safety for infants with unilateral pathologic high-risk retinoblastoma. Results showed enhanced five-year disease-free survival (DFS) among infants receiving three cycles of chemotherapy compared to those…
Cambium Bio Raises Funds for Dry Eye Trials
Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round. This funding will primarily support the development of Elate Ocular, a novel treatment for dry eye disease (DED), through registration-enabling…
Galimedix Starts Phase 1 Trial for Oral GAL-101
Galimedix Therapeutics Inc. has announced the initiation of dosing in a Phase 1 clinical trial for oral GAL-101, an innovative amyloid beta (Aβ) aggregation modulator. The study aims to assess the therapy’s safety, tolerability, and pharmacokinetics, marking a significant step…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…
Prevent Blindness Offers GA Educational Materials
Prevent Blindness, a leading nonprofit organization dedicated to eye health, has announced its fourth annual Geographic Atrophy (GA) Awareness Week, taking place from December 2–8, 2024. Geographic Atrophy, an advanced form of dry age-related macular degeneration (AMD), affects an estimated…
ONS-5010 Falls Short in NORSE EIGHT Trial for Wet AMD
ONS-5010 (LYTENAVA), an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (AMD), failed to meet the noninferiority endpoint in the NORSE EIGHT clinical trial, according to preliminary topline results announced by Outlook Therapeutics. About the NORSE EIGHT Trial…